An understanding of the mechanisms underlying NET-mediated inflammation will empower clinicians to target therapies that can mitigate disease activity & improve outcomes in patients with lupus.
ATAP Board Appointments for 2024-25 Include 2 Distinguished ACR Members
The Alliance for Transparent and Affordable Prescriptions’ board members for the 2024–25 cycle include Marcus Snow, MD, and Howard Blumstein, MD, who both have a strong history of volunteer leadership in the ACR.
After Coalition Meeting, CMS Leadership Agrees to Closer Look at Underwater Biosimilars
The Underwater Biosimilars Coalition shared with the Centers for Medicare & Medicaid Services concerns about problems arising from the average sales price payment methodology and discussed potential options for addressing these challenges.
Interim AMA House of Delegates Meeting Will Discuss Rheumatology Priorities
At the November meeting, the ACR will advance a resolution that addresses increasing access to telemedicine services for Medicare beneficiaries.
The ACR Joins Members of Congress in Call for Medicare Reimbursement Reform
A letter from 233 bipartisan members of Congress last week urged House leadership to replace the 2.8% cut proposed in the FY2025 Physician Fee Schedule with an annual payment update reflective of inflationary pressures before the end of the year. Boost this effort by contacting your legislator today.
Annual RheumPAC Matching Campaign & Donor Appreciation Event
There’s still time to contribute and attend RheumPAC’s event at ACR Convergence 2024. If you haven’t yet made your 2024 donation, this is the best time to do so—thanks to generous champions, every contribution will be amplified.
Sonelokimab Promising for Patients with PsA
A phase 2 clinical trial has demonstrated the effectiveness for multiple doses of subcutaneous sonelokimab for the treatment of adults with active psoriatic arthritis.
15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions
Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
A View from Abroad: The ACR Research Exchange Program
The most recent ACR/APLAR Research Exchange Program gave participants an opportunity to visit Singapore, learn from international research presentations and create connections with colleagues they may never otherwise have met.
Type I IFNs in Cutaneous Lupus & Dermatomyositis
Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 814
- Next Page »